| Daliresp (roflumilast) / AstraZeneca |
NCT01664624: Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes |
|
|
| Completed | 1b | 40 | US | Roflumilast, Daxas, Daliresp, Alogliptin, Nesina, Exenatide, Byetta, Bydureon, Placebo to roflumilast, Placebo to alogliptin | AstraZeneca | Type 2 Diabetes | 11/12 | 11/12 | | |
NCT00940329: Pharmacodynamic/Pharmacokinetic Interactions Between Oral Roflumilast and Inhaled Formoterol |
|
|
| Completed | 1 | 27 | Europe | Roflumilast | AstraZeneca | Healthy | 07/04 | 12/04 | | |
NCT01354782: Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese Subjects |
|
|
| Completed | 1 | 32 | RoW | Roflumilast | AstraZeneca | Chronic Obstructive Pulmonary Disease | 06/11 | 09/11 | | |
NCT02051335: Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults |
|
|
| Completed | 1 | 27 | Europe | Roflumilast, Daxas, Roflumilast placebo, Donepezil, Aricept, Donepezil placebo, Scopolamine, Hyoscine hydrobromide | AstraZeneca | Memory Impairment, Alzheimer's Disease | 05/14 | 05/14 | | |
NCT01888952: Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013) |
|
|
| Completed | 1 | 10 | US | Prednisone, Deltasone, Roflumilast, Daliresp | Anand B. Karnad | Advanced B-cell Lymphoid Malignancies | 01/15 | 01/15 | | |
NCT02079844: Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia |
|
|
| Completed | 1 | 20 | Europe | Roflumilast, DALIRESP®, DAXAS®, Placebo, Second generation antipsychotic | Takeda | Schizophrenia | 06/15 | 06/15 | | |
| Recruiting | 1 | 40 | | roflumilast | The first hospital of Jilin University; Tianyiqinkun Pharmaceutical co., LTD, Xian, Shanxi, Tianyiqinkun Pharmaceutical co., LTD, Xian, Shanxi | chronic obstructive pulmonary disease | | | | |
NCT02363335: The Role of Phosphodiesterase Inhibitors in Incretin Secretion |
|
|
| Completed | 1 | 29 | US | Placebo, Roflumilast/Sitagliptin, Sitagliptin, Roflumilast | National Institute on Aging (NIA) | Healthy Volunteers | 09/16 | 09/16 | | |
| Recruiting | 1 | 100 | US | Exercise, Isoproterenol, Placebo, Bisoprolol Fumarate Tablet 10 mg, Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Carvedilol 50 mg, Roflumilast 500 Mcg Oral Tablet | University of Arizona, National Cancer Institute (NCI) | Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy, Lymphoma, Cell Therapy | 12/28 | 12/28 | | |
NCT04090294: Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis Bronchiectasis |
|
|
| Unknown status | 1 | 35 | NA | Roflumilast, phosphodiestrase 4 inhibitor (PDE4) | Assiut University | Bronchiectasis | 09/20 | 11/20 | | |
ChiCTR2200065536: A single-center, open-label, parallel control study comparing the safety and of a single oral dose of Roflumilast and its active metabolite Roflumilast N-oxide in healthy Chinese and Caucasian volunteers |
|
|
| Completed | 1 | 32 | | Roflumilast ;Roflumilast | China-Japan Friendship Hospital; Tianjin Chase Sun Pharmaceutical Co., Ltd., Tianjin Chase Sun Pharmaceutical Co., Ltd. | COPD | | | | |
NCT03458546: Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma |
|
|
| Completed | 1 | 14 | US | Roflumilast, Daliresp | The University of Texas Health Science Center at San Antonio | Lymphoma, B-Cell | 12/21 | 01/24 | | |
NCT04108377: Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma |
|
|
| Terminated | 1 | 5 | US | Roflumilast, Daliresp, Placebo, Placebo for Roflumilast | University of California, Davis | Asthma | 12/22 | 08/23 | | |
| Withdrawn | 1 | 0 | Canada | Transcranial Magnetic Stimulation, Roflumilast, Placebo oral tablet | University of Calgary | Synaptic Plasticity | 09/23 | 09/23 | | |
| Active, not recruiting | 1 | 20 | Canada | Roflumilast, Active, Placebo, Intermittent theta-burst stimulation transcranial magnetic stimulation, iTBS, Continuous theta-burst stimulation transcranial magnetic stimulation, cTBS | University of Calgary | Other Conditions of Brain | 08/25 | 06/26 | | |
NCT06977711: Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 1 | 10 | US | Loncastuximab, Roflumilast, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone | The University of Texas Health Science Center at San Antonio | Diffuse Large B-cell Lymphoma | 04/26 | 07/26 | | |
NCT05796271: Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy |
|
|
| Withdrawn | 1 | 90 | US | R-Chop and Roflumilast, Daliresp | The University of Texas Health Science Center at San Antonio | Lymphoma, B-Cell | 01/27 | 01/28 | | |
